Immunome, Inc. $IMNM Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC trimmed its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 2.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 808,019 shares of the company’s stock after selling 24,059 shares during the period. Janus Henderson Group PLC owned approximately 0.71% of Immunome worth $17,672,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. T. Rowe Price Investment Management Inc. raised its stake in shares of Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after acquiring an additional 5,003,824 shares during the period. JPMorgan Chase & Co. raised its position in Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after purchasing an additional 2,823,144 shares during the period. Primecap Management Co. CA lifted its stake in shares of Immunome by 55.2% during the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after purchasing an additional 1,667,432 shares in the last quarter. Balyasny Asset Management L.P. purchased a new stake in shares of Immunome in the fourth quarter worth about $30,710,000. Finally, Sofinnova Investments Inc. grew its stake in shares of Immunome by 271.2% in the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after buying an additional 1,182,426 shares in the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Citigroup reissued a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Leerink Partners lowered their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday, May 15th. Truist Financial lifted their price objective on Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Finally, Barclays started coverage on Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 target price on the stock. Thirteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Insider Buying and Selling

In other Immunome news, insider Robert Lechleider sold 55,000 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total value of $1,244,100.00. Following the completion of the sale, the insider directly owned 15,805 shares in the company, valued at $357,509.10. This represents a 77.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Max Rosett sold 60,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $18.23, for a total transaction of $1,093,800.00. Following the sale, the chief financial officer owned 54,037 shares of the company’s stock, valued at $985,094.51. The trade was a 52.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 472,142 shares of company stock worth $10,262,648. Company insiders own 7.21% of the company’s stock.

Immunome Trading Up 1.1%

NASDAQ:IMNM opened at $23.01 on Tuesday. The firm has a market capitalization of $2.61 billion, a PE ratio of -9.67 and a beta of 2.07. The stock has a 50 day moving average of $21.23 and a 200-day moving average of $22.07. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $27.65.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. As a group, analysts predict that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.